Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-bridge Cycle

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2026

Same author

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

JAMA neurology·2026

Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026

Same author

Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study.

Neurology and therapy·2025

Same author

Mesocosm Study of Chemical Treatments on Methane Emissions in Oil Sands Tailings PondsPart I: Focusing on the Change of Microbial Communities and Tailings Dewaterability.

ACS omega·2025

Same author

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Depression in amyotrophic lateral sclerosis.

Nazem Atassi¹, Amanda Cook, Cristiana M E Pineda

¹Massachusetts General Hospital, Harvard Medical School, Boston, USA. NATASSI@PARTNERS.ORG

Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases

|November 25, 2010

Summary

This summary is machine-generated.

Depression affects nearly 35% of people with amyotrophic lateral sclerosis (ALS). However, this comorbidity does not impact research study enrollment in ALS patients.

More Related Videos

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Area of Science:

Neurology
Psychiatry

Background:

Depression is a frequent yet under-recognized comorbidity in amyotrophic lateral sclerosis (ALS).
Understanding depression prevalence and its impact on research participation is crucial for ALS patient care and clinical trial development.

Purpose of the Study:

To prospectively estimate the prevalence of depression among individuals with ALS.
To investigate the influence of depression on enrollment in research studies for ALS.
To identify potential predictors of depression in the ALS population.

Main Methods:

Prospective study involving 127 people with ALS.
Utilized the ALS Depression Inventory (ADI-12) to assess depression.
Collected data on ALS symptoms, medications, functional status, and research enrollment preferences.

Main Results:

Mild and severe depression prevalence was 29% and 6%, respectively, in the ALS cohort.
Over one-third of ALS patients received antidepressants for various conditions.
Depression prevalence did not correlate with disease duration or progression and did not affect research enrollment decisions.
Anxiety was the only ALS-related symptom that predicted depression.

Conclusions:

Major depression is less prevalent in this ALS cohort compared to the general population.
ALS-related symptoms can mask depression, complicating diagnosis.
Depression does not hinder enrollment in ALS clinical trials, suggesting research accessibility is not compromised by mood disorders.